M&A buzz: ViroPharma could go for $60 per share in buyout

Ryan McBride

The rare-disease drug specialist has been generating all week after reports that the company brought on the services of Goldman Sachs to hunt for potential acquisition offers.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS